Lantheus's Imaging Agent Can Assess PD-L1 Expression for Immunotherapy In Cancer Patients

Loading...
Loading...
  • Lantheus Holdings Inc LNTH presented preliminary results of the PD-L1 Expression in Cancer (PECan) study from the first ten non-small cell lung cancer (NSCLC) patients.
  • The PECan study plans to enroll 15 advanced NSCLC and 15 melanoma patients. 
  • NM-01, a proprietary technetium 99m SPECT/CT imaging agent, is currently under development to assess PD-L1 expression in cancer cells.
  • The results suggest that NM-01 can identify patients who will respond to checkpoint inhibitor therapies and monitor early response in non-small cell lung cancer (NSCLC) pending a further and ongoing investigation.
  • In the preliminary analysis, investigators could evidence intertumoral heterogeneity of PD-L1 expression between primary tumors and metastases. 
  • Further, baseline NM-01 SPECT/CT imaging could predict early metabolic 18F-FDG PET/CT response to anti-PD-L1 therapy in primary and metastatic tumors. 
  • Following therapy, PD-L1 expression measured by NM-01 SPECT/CT imaging demonstrated stability or a reduction in most responding lesions.
  • In a separate study, Lantheus' PYLARIFY AI, the company's artificial intelligence (AI) platform, demonstrated significant improvement in lesion detection compared to manual reads. 
  • PYLARIFY AI is developed to assist in the standardized quantification of PSMA PET/CT scans. 
  • Price Action: LNTH shares closed 4.89% lower at $63.85 on Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...